ResMed expands global doctor training to screen weight loss patients for sleep apnea
ResMed Inc. plans to take its doctor education program global to screen GLP-1 weight-loss drug users for sleep apnea as part of a strategic growth initiative.
洞察:
ResMed has announced it will expand its doctor education program globally to encourage the screening of patients seeking GLP-1 weight-loss drugs for sleep apnea. The company frames the rapid adoption of these pharmaceutical treatments as a significant demand tailwind for its medical devices. This announcement comes after ResMedreported an 11 percent jump in second-quarter profit last week.
The medical technology firm is targeting the increased flow of patients into primary care clinics where they are typically assessed for comorbidities. Mick Farrell mick farrell, the chief executive of ResMed, characterized the GLP-1 boom as a tailwind rather than a threat to the company’s core business. He noted that the central challenge is determining how much of that increased patient interest ResMedcan successfully capture.
